www rich9 agent

www rich9 agent Stock Market Today: Nasdaq Nabs New High After Jobs DataGeneration Beta is about to enter the world. Babies born between 2025 and 2039 will be , according to a blog post from demographer and consultant , who has been credited used to group people by their birth years. The start of Gen Beta at the end of 2024, according to McCrindle's timeline, will also mark the end of Gen Alpha births, which he sees as taking place between 2010 and 2024. By 2035, McCrindle wrote, members of Gen Beta — who follow Gen Alpha, or "Gen Z," as well as Generation Y, also known as millennials — “will make up 16% of the global population” and many of them “will live to see the 22nd century.” Additionally, Gen Beta is expected to make up about 19% of the world’s workforce by that same year. “Generation Beta represents the dawn of a new era,” McCrindle wrote in his new blog post. “They will grow up in a world shaped by breakthroughs in technology, evolving social norms, and an increasing focus on sustainability and global citizenship.” Gen Beta will be the children of millennials and older members of Gen Z, according to McCrindle. They will also enter a world where physical and digital worlds “will be seamless” and “where AI and automation are fully embedded in everyday life,” McCrindle predicted. “Their formative years will be marked by a greater emphasis on personalisation — AI algorithms will tailor their learning, shopping, and social interactions in ways we can only begin to imagine today,” McCrindle wrote. But Gen Beta will also face “major societal challenges” in their lifetimes such as the continued effects of climate change, a shifting global population and “rapid” urbanization in more parts of the world. Related: Given that they'll likely have more eco-minded parents in millenials and Gen Z, Gen Beta will be “more globally minded, community-focused, and collaborative than ever before," McCrindle expects. “Their upbringing will emphasise the importance of innovation," he wrote, 'not just for convenience, but for solving the pressing challenges of their time.” Read the original article on

ISLAMABAD: A District and Sessions Court granted interim bail to former first lady Bushra Bibi until January 13, in four cases related to the November 26th protests. District and Sessions Judge Shabbir Bhatti heard the interim bail applications filed by Bushra Bibi in the Nov 26 protest cases. The court granted her interim bail till January 13 against bonds of Rs50,000. The PTI founder’s wife, Bushra Bibi appeared before court along with her lawyers for interim bail in four cases registered against her at Tarnol police station, and three at Ramana police station. On December 21, an Anti-Terrorism Court (ATC) in Rawalpindi approved interim bail of Bushra Bibi in 32 cases till January 13, her counsel said. According to details, PTI founder’s wife appeared before the ATC along with her counsel and sought bail in total of 32 cases, including 23 pertaining to May 9 violence. The former first lady has been grated interim bail in 32 cases registered in Rawalpindi, Attock and Chakwal. She appeared in court at the hearing and provided the necessary surety bonds to obtain interim bail. Former first lady Bushra Bibi left the court premises after the bail was granted, and her next court appearance is set for mid-January. Her counsel, Faisal Malik argued that the cases registered against Bushra Bibi are ‘politically motivated and aimed at vengeance’. On Nov 13, Imran issued a “final call” for nationwide protests on Nov 24, demanding the restoration of the PTI’s electoral mandate, the release of detained party members, and the reversal of the 26th Amendment which he said had strengthened a “dictatorial regime”. At least six lives were lost in the three days of protests, which included a policeman and three Rangers officials who were knocked down by a speeding vehicle, officials and hospital sources said. Claims and counter-claims over deaths purportedly caused by law-enforcement action against the PTI marchers remain a major bone of contention between the government and the opposition party. Save my name, email, and website in this browser for the next time I comment. Δ document.getElementById( "ak_js_1" ).setAttribute( "value", ( new Date() ).getTime() );

Daily Post Nigeria Police detain man for slitting friend’s throat in Kogi Home News Politics Metro Entertainment Sport Metro Police detain man for slitting friend’s throat in Kogi Published on December 26, 2024 By Ochogwu Sunday A second-year undergraduate of Confluence University of Science and Technology, CUSTECH, Osara in Kogi, Usman Tijani, has been attacked and brutally injured by his friend, Abdulmuqeet Musari, Police have said. The Kogi Command’s Spokesman, SP Williams Aya, confirmed the incident and detention of the suspect by the command to NAN in Lokoja on Thursday. Aya said: “The suspect has been in our custody, and the investigation is ongoing. “He will be arraigned on completion of the investigation.” Narrating the incident in a statement, the Chairman, Adavi Local Government Area, LGA, Mr Bashiru Okatenwu, stated that the incident occurred at about 8 pm on December 23, around Adavi Burial Ground, New Zango in Adavi. According to the statement issued to NAN by Okatenwu’s Media Aide, Suleiman Acheneje, in Adavi, the victim is a 200-level student of the Department of Cyber Security in CUSTECH. “In the late hours of December 23, between 7 pm and 8 pm precisely, an unforeseen circumstance happened around Adavi Burial Ground, where a young boy, named Usman Tijani, got attacked by one of the bad eggs we still have in our society. “Usman was brutally injured by Abdulmuqeet Musari, whose intent was, no doubt, to kill him. “The victim was found nearly dead and rescued around 2 am in New Zango, Adavi LGA, where he was immediately rushed to Lokoja and has since been receiving treatment in a hospital there. “The culprit was already in the run but Kudos to the people’s Governor, the Chairman Of Adavi, and their Security intel, as they were able to apprehend the culprit in Ekiti,” Okatenwu said. He assured the good people of Adavi of his administration’s commitment to ensuring adequate security for their lives and property. Meanwhile, a relation of the victim, Zainab Avosuahu, who commented on the issue through her Meta, Facebook page post on Tuesday, said the suspect allegedly lured her nephew into the bush, collected N200,000 from him and slit his throat. Avosuahu stated: “The 19-year-old victim, who runs a POS business, is currently undergoing surgery in a Lokoja hospital. Related Topics: kogi police Don't Miss Police recover vehicle of kidnapped Anambra lawmaker You may like Police recover vehicle of kidnapped Anambra lawmaker Murder of retired Niger perm sec: Prime suspect dies in police custody Police arrest ex-convict for armed robbery two days after release from jail Police foil kidnap attempt in Katsina, rescue 10 hostages Imo police lose two officers, kill three kidnapping suspects Police enhance security measures for festive season in Taraba Advertise About Us Contact Us Privacy-Policy Terms Copyright © Daily Post Media Ltd

INDIANAPOLIS (WISH) — A Jan. 6 riot defendant from Indiana who escaped his prison sentence is applying for refugee status in Canada. Antony Vo in November told I-Team 8 he still believes President-elect Donald Trump will deliver pardons to all Jan. 6 riot defendants once he’s back in the Oval Office on Jan. 20. But, for now, Vo is waiting for that day in Canada as he goes through the country’s asylum process. Vo said his immediate plans include skiing. He and his mother, Annie Vo, were convicted as nonviolent participants in the Jan. 6 riot at the U.S. Capitol, but Antony never served his nine-month sentence. “The majority of Jan. 6 people have been held more than accountable,” Antony Vo said. Vo says he’s already gone through medical evaluations but canceled a refugee eligibility hearing with Canadian authorities. He’s waiting for assurances that he won’t be detained and sent back to the U.S. Vo’s application for political refugee status makes sweeping claims that he’s the victim of a government conspiracy, writing that his conviction is “purely political persecution.” The application, obtained by I-Team 8, states a legal fund set up for Jan. 6 riot defendants is helping Vo pay for an attorney. He has no plans to turn himself in. “Our country, ourselves, we have a long history of standing up for our rights, what we believe in.” Canadian officials say that, due to privacy legislation, the government cannot comment on specific refugee cases. But, one of the factors officials will use to evaluate a refugee claim is whether that person has committed a serious crime. The U.S. Marshals Service by Friday afternoon had not responded to requests for an update on the search for Vo.Edwardsville golfer Mason Lewis will carry on family legacy at SMU

With Trump on the way, advocates look to states to pick up medical debt fightThe day some colleagues and I launched Canada's National Observer in 2015 , we thought climate change was still years away. None of us imagined how quickly it would arrive. A decade later, we’re racing against time. But solutions are emerging, and they’re coming rapidly. Through Canada’s National Observer’s solutions-focused reporting, we’ve highlighted so many innovative policies, breakthrough technologies, and community-driven initiatives this year, solutions that are making a real difference. These stories show that progress is not only possible, it’s happening – even in the face of significant challenges, and these stories inspire action across Canada and beyond. Building on Our Impact Your support has also enabled us to expose corporate influence networks and the money behind climate denial. When our reporting triggered parliamentary inquiries and drove policy changes, that was your impact in action. Your support has also helped us report on dozens of solutions this year — stories that spark hope and show a path forward. Over the past few weeks, you’ve heard directly from our editors and journalists about the most impactful stories they did in 2024. Those letters show how your support powered investigations that made a difference — holding decision-makers accountable, exposing corruption, and showcasing the wonderful solutions that drive change. As our winter campaign aims to raise $150,000, we want to expand our capacity to do even more next year, because the news is not always negative. This funding will allow us to: Your donation today will ensure we have the resources to amplify stories of hope and action while getting the public the necessary information. We reached 2.5 million Canadians last year and we hope to expand our audience in 2025 through paid campaigns that introduce new readers to CNO. But we can’t do much without your help. Tax receipts are available for donations of $100+, see specific instructions at the end. The Stakes for Canada In 2025, the risks to climate policy are closer to home than ever. The forces of climate denial are becoming more sophisticated, trading outright rejection for greenwashing tactics that delay meaningful action. At the same time, cross-border misinformation campaigns are influencing Canadian public opinion and policy decisions. Despite these challenges, I remain cautiously optimistic. Solutions exist, and they are within reach. With accurate reporting, governments and businesses can be held accountable to act on them. Your Role in the Solution If you’re reading this, you’re already part of the CNO community. Your support powers everything we do. You make it possible for us to produce journalism that informs policymakers, sparks change, and inspires action. Thank you for your support to date. Next year will bring new challenges — but also new opportunities to create change. With your help, we can hold powerful interests accountable, shine a light on the path forward, and ensure that stories of progress and possibility are told. Your support has never been more important. Let’s continue this work together

Prospera Financial Services Inc Has $485,000 Stock Holdings in iShares MSCI EAFE Min Vol Factor ETF (BATS:EFAV)Banque Cantonale Vaudoise lowered its holdings in shares of iShares Core High Dividend ETF ( NYSEARCA:HDV – Free Report ) by 72.6% during the third quarter, Holdings Channel reports. The firm owned 320 shares of the exchange traded fund’s stock after selling 850 shares during the period. Banque Cantonale Vaudoise’s holdings in iShares Core High Dividend ETF were worth $38,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also modified their holdings of the business. Centaurus Financial Inc. increased its position in iShares Core High Dividend ETF by 8.4% during the second quarter. Centaurus Financial Inc. now owns 1,160 shares of the exchange traded fund’s stock worth $126,000 after buying an additional 90 shares during the last quarter. Straight Path Wealth Management raised its stake in shares of iShares Core High Dividend ETF by 1.1% in the 3rd quarter. Straight Path Wealth Management now owns 9,317 shares of the exchange traded fund’s stock valued at $1,096,000 after acquiring an additional 97 shares in the last quarter. Jaffetilchin Investment Partners LLC lifted its holdings in iShares Core High Dividend ETF by 0.7% in the 2nd quarter. Jaffetilchin Investment Partners LLC now owns 14,647 shares of the exchange traded fund’s stock worth $1,592,000 after purchasing an additional 99 shares during the last quarter. Parsons Capital Management Inc. RI boosted its position in iShares Core High Dividend ETF by 0.9% during the second quarter. Parsons Capital Management Inc. RI now owns 11,160 shares of the exchange traded fund’s stock worth $1,213,000 after purchasing an additional 100 shares during the period. Finally, WealthShield Partners LLC grew its holdings in iShares Core High Dividend ETF by 3.6% during the second quarter. WealthShield Partners LLC now owns 2,956 shares of the exchange traded fund’s stock valued at $321,000 after purchasing an additional 104 shares during the last quarter. iShares Core High Dividend ETF Trading Up 0.5 % Shares of iShares Core High Dividend ETF stock opened at $120.79 on Friday. The firm has a fifty day simple moving average of $118.25 and a 200-day simple moving average of $114.11. The stock has a market capitalization of $11.41 billion, a price-to-earnings ratio of 13.82 and a beta of 0.55. iShares Core High Dividend ETF has a 1-year low of $98.17 and a 1-year high of $121.23. iShares Core High Dividend ETF Profile The iShares Core High Dividend ETF (HDV) is an exchange-traded fund that is based on the Morningstar Dividend Yield Focus index. The fund tracks a dividend-weighted index of 75 high-yielding US equities, screened for high earnings potential and dividend sustainability. HDV was launched on Mar 29, 2011 and is managed by BlackRock. Featured Stories Want to see what other hedge funds are holding HDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Core High Dividend ETF ( NYSEARCA:HDV – Free Report ). Receive News & Ratings for iShares Core High Dividend ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Core High Dividend ETF and related companies with MarketBeat.com's FREE daily email newsletter .

`Rohit Sharma kaun hai?`: This and other interesting things Indians asked Alexa

Josh Hawley thinks America needs a religious revival. Is this man helping him find itManmohan Singh's father may have believed his bookworm son would one day lead India, but the understated technocrat with the trademark blue turban, who died Thursday at the age of 92, never dreamed it would actually happen. Singh was pitchforked into leading the world's largest democracy in 2004 by the shock decision of Congress leader Sonia Gandhi to turn down the role after leading the party to an upset win over the ruling Hindu nationalists. He oversaw an economic boom in Asia's fourth-largest economy in his first term, although slowing growth in later years marred his second stint. Known as "Mr Clean", Singh nonetheless saw his image tarnished during his decade-long tenure when a series of corruption cases became public. As finance minister in the early 1990s, he was hailed at home and abroad for initiating big-bang reforms that opened India's inward-looking economy to the world. Known as a loyalist to the Gandhi political dynasty, Singh studied economics to find a way to eradicate poverty in the vast nation and never held elected office before becoming PM. But he deftly managed the rough and tumble of Indian politics -- even though many said Sonia Gandhi, the Italian-born widow of the assassinated Rajiv Gandhi, was the power behind the throne. - Streetlight studying - Born in 1932 in the mud-house village of Gah in what is now Pakistan, Singh moved to the holy Sikh city of Amritsar as a teenager around the time the subcontinent was split at the end of British rule into mainly Hindu India and Muslim Pakistan. His father was a dry-fruit seller in Amritsar, and he had nine brothers and sisters. He was so determined to get an education he would study at night under streetlights because it was too noisy at home, his brother Surjit Singh told AFP in 2004. "Our father always used to say Manmohan will be the prime minister of India since he stuck out among the 10 children," said Singh. "He always had his nose in a book." Singh won scholarships to attend both Cambridge, where he obtained a first in economics, and Oxford, where he completed his PhD. He worked in a string of senior civil posts, served as a central bank governor and also held various jobs with global agencies such as the United Nations. Singh was tapped in 1991 by then Congress prime minister P.V. Narasimha Rao to reel India back from the worst financial crisis in its modern history -- currency reserves had sunk so low the country was on the brink of defaulting on foreign loans. Singh unleashed sweeping change that broke sharply with India's Soviet-style state-directed economy. - 'History will be kinder' - In his first term he steered the economy through a period of nine-percent growth, lending the country the international clout it had long sought. He also sealed a landmark nuclear deal with the US that he said would help India meet its growing energy needs. But by 2008 there was growing disquiet among the ruling alliance's left-leaning parties about the pact, while high inflation -- notably food and fuel prices -- hit India's poor hard. Still, voters remained drawn to his calm, pragmatic persona, and in 2009 Congress steered its alliance to a second term. Singh vowed to step up financial reforms to drive economic growth, but he came under increasing fire from critics who said he had done nothing to stop a string of corruption scandals on his watch. Several months before the 2014 elections, Singh said he would retire after the polls, with Sonia Gandhi's son Rahul earmarked to take his place if Congress won. But Congress crashed to its worst-ever result at that time as the Hindu-nationalist Bharatiya Janata Party, led by Narendra Modi, won a landslide. More recently, an unflattering book by a former aide titled "The Accidental Prime Minister" portrayed him as timid and controlled by Sonia Gandhi. Singh -- who said historians would be kinder to him than contemporary detractors -- became a vocal critic of Modi's economic policies, and more recently warned about the risks that rising communal tensions posed to India's democracy. pmc-grk/abh/fox/leg/sms

CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $Cruise into this holiday season with a non-traditional vacation

Laurentian Bank reports profits up for the quarter but down for the year

Trump asks US Supreme Court to delay TikTok banA man, a (bad) plan, a canal, Panama